Literature DB >> 11068184

Mucopolysaccharidosis type IIIB: characterisation and expression of wild-type and mutant recombinant alpha-N-acetylglucosaminidase and relationship with sanfilippo phenotype in an attenuated patient.

G Yogalingam1, B Weber, J Meehan, J Rogers, J J Hopwood.   

Abstract

Mucopolysaccharidosis type IIIB (MPS-IIB) is a lysosomal storage disorder characterised by the defective degradation of heparan sulfate due to a deficiency of alpha-N-acetylglucosaminidase (NAG). The clinical severity of MPS-IIIB ranges from an attenuated to severely affected Sanfilippo phenotype. This paper describes the expression and characterisation of wild-type recombinant NAG and the molecular characterisation of a previously identified R297X/F48L compound heterozygous MPS-IIIB patient with attenuated Sanfilippo syndrome. We have previously shown R297X to be the most common mutation in a cohort of Dutch and Australian patients, occurring at a frequency of approximately 12.5%. To date F48L has only been described in the proband. To determine the contribution of each mutation to the overall clinical phenotype of the patient, both mutant alleles were engineered into the wild-type NAG cDNA and expressed in Chinese hamster ovary cells. The wild-type NAG and F48L mutant alleles were also retrovirally expressed in MPS-IIIB skin fibroblasts. Residual NAG activity and the stability and maturation of immunoprecipitated NAG were determined for wild-type NAG and mutant NAG. The combined biochemical phenotypes of the two NAG mutant alleles demonstrated a good correspondence with the observed attenuated Sanfilippo phenotype of the patient.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11068184     DOI: 10.1016/s0925-4439(00)00066-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  12 in total

1.  A GLP-Compliant Toxicology and Biodistribution Study: Systemic Delivery of an rAAV9 Vector for the Treatment of Mucopolysaccharidosis IIIB.

Authors:  Aaron S Meadows; F Jason Duncan; Marybeth Camboni; Kathryn Waligura; Chrystal Montgomery; Kimberly Zaraspe; Bartholomew J Naughton; William G Bremer; Christopher Shilling; Christopher M Walker; Brad Bolon; Kevin M Flanigan; Kim L McBride; Douglas M McCarty; Haiyan Fu
Journal:  Hum Gene Ther Clin Dev       Date:  2015-12       Impact factor: 5.032

2.  Correction of mucopolysaccharidosis type IIIb fibroblasts by lentiviral vector-mediated gene transfer.

Authors:  Guglielmo R D Villani; Antonia Follenzi; Borghina Vanacore; Carmela Di Domenico; Luigi Naldini; Paola Di Natale
Journal:  Biochem J       Date:  2002-06-15       Impact factor: 3.857

3.  Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery.

Authors:  Haiyan Fu; Julianne Dirosario; Smruti Killedar; Kimberly Zaraspe; Douglas M McCarty
Journal:  Mol Ther       Date:  2011-03-08       Impact factor: 11.454

4.  Emerging links between pediatric lysosomal storage diseases and adult parkinsonism.

Authors:  Daniel Ysselstein; Joshua M Shulman; Dimitri Krainc
Journal:  Mov Disord       Date:  2019-02-06       Impact factor: 10.338

5.  Structural and mechanistic insight into the basis of mucopolysaccharidosis IIIB.

Authors:  Elizabeth Ficko-Blean; Keith A Stubbs; Oksana Nemirovsky; David J Vocadlo; Alisdair B Boraston
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-28       Impact factor: 11.205

6.  Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates.

Authors:  Darren A Murrey; Bartholomew J Naughton; F Jason Duncan; Aaron S Meadows; Tierra A Ware; Katie J Campbell; William G Bremer; Christopher M Walker; Laurie Goodchild; Brad Bolon; Krista La Perle; Kevin M Flanigan; Kim L McBride; Douglas M McCarty; Haiyan Fu
Journal:  Hum Gene Ther Clin Dev       Date:  2014-04-10       Impact factor: 5.032

7.  Genotype to Phenotype: Identification of Mucopolysaccharidosis Type IIIB (Sanfilippo's B) Case Using Whole Exome Sequencing.

Authors:  Muhsin Elmas; Basak Gogus; Furkan Kılıçarslan; Aysegul Bukulmez; Mustafa Solak
Journal:  J Pediatr Genet       Date:  2020-03-31

8.  Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type B.

Authors:  Coy D Heldermon; Anne K Hennig; Kevin K Ohlemiller; Judith M Ogilvie; Erik D Herzog; Annalisa Breidenbach; Carole Vogler; David F Wozniak; Mark S Sands
Journal:  PLoS One       Date:  2007-08-22       Impact factor: 3.240

9.  Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice.

Authors:  C D Heldermon; E Y Qin; K K Ohlemiller; E D Herzog; J R Brown; C Vogler; W Hou; J L Orrock; B E Crawford; M S Sands
Journal:  Gene Ther       Date:  2013-03-28       Impact factor: 5.250

10.  A model of mucopolysaccharidosis type IIIB in pigs.

Authors:  Qiang Yang; Xueyan Zhao; Yuyun Xing; Chao Jiang; Kai Jiang; Pan Xu; Weiwei Liu; Jun Ren; Lusheng Huang
Journal:  Biol Open       Date:  2018-10-26       Impact factor: 2.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.